Table of Content

Open Access iconOpen Access

ARTICLE

Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution

Wang Fangzheng*†1, Jiang Chuner‡1, Ye Zhiming*†, Liu Tongxin*†, Yan Fengqin*†, Wang Lei*†, Li Bin*†, Hu Fujun*†, Chen Ming*†, Qin Weifeng*†, Fu Zhenfu*†

* Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China
† Zhejiang Key Laboratory of Radiation Oncology, Zhejiang, Hangzhou, P.R. China
‡ Department of Breast Surgery, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China

Oncology Research 2018, 26(2), 277-287. https://doi.org/10.3727/096504017X15079846743590

Abstract

In this retrospective review of a single institution’s experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC) were studied. Between August 2008 and March 2014, 39 newly diagnosed patients with stages III–IV NPC were treated with IMRT, chemotherapy, and nimotuzumab. Twenty patients were diagnosed with stage III (51.3%), 14 with stage IVA (35.9%), and 5 with stage IVB (12.8%) disease. All patients received at least one cycle of cisplatin-based induction chemotherapy followed by IMRT and more than nine cycles of nimotuzumab at 200 mg/week. Acute and late radiation-related toxicities were graded according to the Acute and Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group. Accumulated survival was calculated according to the Kaplan–Meier method. The log-rank test was used to compare survival differences. With a median follow-up of 46 months (range, 22–86 months), the estimated 3-year local recurrence-free, regional recurrence-free, distant metastasis-free, progression failure-free, and overall survival rates were 92.1%, 89.7%, 82.5%, 77.6%, and 86.8%, respectively. Univariate analysis showed that clinical stage and the cycle of induction chemotherapy were related with prognosis. The median cycle for the addition of nimotuzumab was 12 weeks. Grade 3 radiation-induced mucositis was observed in 15.8% of the treated patients. No skin rash or infusion reaction was observed, which is distinctly different from what was reported in patients treated with nimotuzumab. The major toxicities observed were grades I–II mucositis and leukocytopenia. Long-term use of nimotuzumab plus IMRT showed promising outcomes in terms of locoregional control and survival, without increasing the incidence of radiation-related toxicities in patients.

Keywords


Cite This Article

APA Style
Fangzheng, W., Chuner, J., Zhiming, Y., Tongxin, L., Fengqin, Y. et al. (2018). Long-term use of nimotuzumab in combination with intensity-modulated radiotherapy and chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma: experience of a single institution. Oncology Research, 26(2), 277-287. https://doi.org/10.3727/096504017X15079846743590
Vancouver Style
Fangzheng W, Chuner J, Zhiming Y, Tongxin L, Fengqin Y, Lei W, et al. Long-term use of nimotuzumab in combination with intensity-modulated radiotherapy and chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma: experience of a single institution. Oncol Res. 2018;26(2):277-287 https://doi.org/10.3727/096504017X15079846743590
IEEE Style
W. Fangzheng et al., "Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution," Oncol. Res., vol. 26, no. 2, pp. 277-287. 2018. https://doi.org/10.3727/096504017X15079846743590



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 61

    View

  • 55

    Download

  • 0

    Like

Share Link